-
Je něco špatně v tomto záznamu ?
Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
C. Sciammarella, A. Luce, F. Riccardi, C. Mocerino, R. Modica, M. Berretta, G. Misso, AM. Cossu, A. Colao, G. Vitale, A. Necas, J. Fedacko, M. Galdiero, P. Correale, A. Faggiano, M. Caraglia, A. Capasso, A. Grimaldi,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
PubMed Central
od 2011
Europe PubMed Central
od 2011
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
PubMed
32766136
DOI
10.3389/fonc.2020.01047
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Somatostatin analogs mantain their major role in the treatment of patients with advanced neuroendocrine tumors (NETs) and have multiple modulatory effects on the immune system. Here, we evaluated the effects of lanreotide treatment on expression of Th1, Th2 cytokine patterns in serum of patients with NETs and in bronchial and pancreatic NET cell lines. Our results showed that lanreotide treatment promoted a Th1 cytotoxic immune-phenotype in patients with NETs originated by intestinal sites. Similar results were obtained also in vitro where lanreotide induced expression of Th1 cytokines only in pancreatic and not in bronchial-derived NET cell lines. It seems, therefore, that cytokinomics can represent a useful tool for the identification of tumor biomarkers for the early diagnosis and evaluation of the response to therapy in NET patients. To avoid the drug-resistance induced by everolimus (mTOR inhibitor), we made the pancreatic NET cell line resistant to this drug. After treatment with lanreotide we found that the drug reduced its viability compared to that of sensitive cells. These data may have direct implications in design of future translation combination trial on NET patients.
Department of Clinical Medicine and Surgery University Federico 2 of Naples Naples Italy
Department of Experimental Medicine Division of Endocrinology Sapienza University of Rome Rome Italy
Department of Experimental Medicine University of Campania Luigi Vanvitelli Naples Italy
Department of Precision Medicine University of Campania Luigi Vanvitelli Naples Italy
Medical Oncology Unit Bianchi Melacrino Morelli Grand Metropolitan Hospital Reggio Calabria Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20022010
- 003
- CZ-PrNML
- 005
- 20201204093605.0
- 007
- ta
- 008
- 201125s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fonc.2020.01047 $2 doi
- 035 __
- $a (PubMed)32766136
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Sciammarella, Concetta $u Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. Department of Clinical Medicine and Surgery, University "Federico II" of Naples, Naples, Italy.
- 245 10
- $a Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus / $c C. Sciammarella, A. Luce, F. Riccardi, C. Mocerino, R. Modica, M. Berretta, G. Misso, AM. Cossu, A. Colao, G. Vitale, A. Necas, J. Fedacko, M. Galdiero, P. Correale, A. Faggiano, M. Caraglia, A. Capasso, A. Grimaldi,
- 520 9_
- $a Somatostatin analogs mantain their major role in the treatment of patients with advanced neuroendocrine tumors (NETs) and have multiple modulatory effects on the immune system. Here, we evaluated the effects of lanreotide treatment on expression of Th1, Th2 cytokine patterns in serum of patients with NETs and in bronchial and pancreatic NET cell lines. Our results showed that lanreotide treatment promoted a Th1 cytotoxic immune-phenotype in patients with NETs originated by intestinal sites. Similar results were obtained also in vitro where lanreotide induced expression of Th1 cytokines only in pancreatic and not in bronchial-derived NET cell lines. It seems, therefore, that cytokinomics can represent a useful tool for the identification of tumor biomarkers for the early diagnosis and evaluation of the response to therapy in NET patients. To avoid the drug-resistance induced by everolimus (mTOR inhibitor), we made the pancreatic NET cell line resistant to this drug. After treatment with lanreotide we found that the drug reduced its viability compared to that of sensitive cells. These data may have direct implications in design of future translation combination trial on NET patients.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Luce, Amalia $u Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
- 700 1_
- $a Riccardi, Ferdinando $u Oncology Unit, AORN Cardarelli, Naples, Italy.
- 700 1_
- $a Mocerino, Carmela $u Oncology Unit, AORN Cardarelli, Naples, Italy.
- 700 1_
- $a Modica, Roberta $u Department of Clinical Medicine and Surgery, University "Federico II" of Naples, Naples, Italy.
- 700 1_
- $a Berretta, Massimiliano $u Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto Nazionale Tumori CRO, Aviano, Italy.
- 700 1_
- $a Misso, Gabriella $u Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
- 700 1_
- $a Cossu, Alessia Maria $u Laboratory of Precision and Molecular Oncology, Institute of Genetic Research, Biogem Scarl, Avellino, Italy.
- 700 1_
- $a Colao, Annamaria $u Department of Clinical Medicine and Surgery, University "Federico II" of Naples, Naples, Italy.
- 700 1_
- $a Vitale, Giovanni $u Laboratory of Geriatric and Oncologic Neuroendocrinology Research, Istituto Auxologico Italiano, IRCCS, Milan, Italy. Department of Clinical Sciences and Community Health (DISCCO), University of Milan, Milan, Italy.
- 700 1_
- $a Necas, Alois $u CEITEC - Central European Institute of Technology, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czechia.
- 700 1_
- $a Fedacko, Jan $u 1st Department of Internal Medicine, Centre of Excellency for Atherosclerosis Research, University of Pavol Jozef Safarik, Košice, Slovakia.
- 700 1_
- $a Galdiero, Marilena $u Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
- 700 1_
- $a Correale, Pierpaolo $u Medical Oncology Unit, "Bianchi-Melacrino-Morelli" Grand Metropolitan Hospital, Reggio Calabria, Italy.
- 700 1_
- $a Faggiano, Antongiulio $u Department of Experimental Medicine, Division of Endocrinology, Sapienza University of Rome, Rome, Italy.
- 700 1_
- $a Caraglia, Michele $u Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. Laboratory of Precision and Molecular Oncology, Institute of Genetic Research, Biogem Scarl, Avellino, Italy.
- 700 1_
- $a Capasso, Anna $u Department of Oncology, Livestrong Cancer Institutes, Dell Medical School, The University of Texas, Austin, TX, United States.
- 700 1_
- $a Grimaldi, Anna $u Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
- 773 0_
- $w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 10, č. - (2020), s. 1047
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32766136 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201204093602 $b ABA008
- 999 __
- $a ind $b bmc $g 1591718 $s 1112682
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 10 $c - $d 1047 $e 20200707 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
- LZP __
- $a Pubmed-20201125
